Palliative local radiotherapy in the treatment of tumor-stage cutaneous T-cell lymphoma/mycosis fungoides.
- Author:
Chen-chen XU
1
,
2
;
Tao ZHANG
1
;
Tao WANG
1
;
Jie LIU
1
;
Yue-hua LIU
1
;
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Agents; administration & dosage; therapeutic use; Chemoradiotherapy, Adjuvant; methods; Disease-Free Survival; Female; Humans; Interferons; administration & dosage; therapeutic use; Lymphoma, T-Cell, Cutaneous; drug therapy; pathology; radiotherapy; Male; Middle Aged; Mycosis Fungoides; drug therapy; pathology; radiotherapy; Neoplasm Staging; PUVA Therapy; methods; Palliative Care; methods; Radiotherapy Dosage; Skin Neoplasms; drug therapy; pathology; radiotherapy; Treatment Outcome
- From: Chinese Medical Sciences Journal 2014;29(1):33-37
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo determine the efficacy of palliative radiotherapy in treating tumor-stage cutaneous T-cell lymphoma/mycosis fungoides (MF).
METHODSFrom January 2008 to January 2013, a total of 11 patients with tumor-stage MF were treated with local radiation therapy in Peking Union Medical College Hospital. The median age of these patients was 53.36 ± 14.45 years. Female-male ratio was 1:1.2. The average course of disease was 10.82 ± 3.37 years. All the patients were treated with local electronic beam irradiation with a total median dosage of 48.55 ± 9.51 (40-74) Gy in an average of 24.55 ± 5.57 (20-40) fractions, 5 fractions per week.
RESULTSThe median follow-up time was 55.27 ± 29.3 (13-103) months. No severe acute or chronic side effects of irradiation were observed. Complete clinical response (CR) rate of the radiated sites was 54.5% (6/11), partial response (PR) rate was 36.4% (4/11), and the overall response rate (CR+PR) was 90.9%. One patient showed no response.
CONCLUSIONLocal radiotherapy with psolaren plus ultraviolet A and/or interferon maintaining treatment is an effective palliative therapy in the treatment of tumor-stage MF patients.
